Migraine and calcitonin gene-related peptide pathway antibodies: a treatment route in tertiary care

Abstract

Inhibiting the calcitonin gene-related peptide (CGRP) pathway is a new treatment to prevent migraines. CGRP is a potent vasodilator and is a key neuropeptide which plays a crucial role in migraine pathophysiology. Following the European Medicines Agency's approval of three CGRP pathway monoclonal antibodies (mAbs), erenumab, fremanezumab and galcanezumab, the authors proceeded with early adoption in practice. Here they summarise and share their patient treatment pathway using erenumab, the first mAb to become clinically available.